Detalhe da pesquisa
1.
How I treat myeloproliferative neoplasms in pregnancy.
Blood
; 143(9): 777-785, 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38145575
2.
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib.
Blood
; 143(2): 178-182, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37963262
3.
Essential thrombocythemia: challenges in clinical practice and future prospects.
Blood
; 141(16): 1943-1953, 2023 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36379024
4.
Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives.
Cancer
; 2024 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38373144
5.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Lancet
; 401(10373): 269-280, 2023 01 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36709073
6.
Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms.
Genome Res
; 31(8): 1381-1394, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34244229
7.
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Blood
; 139(19): 2931-2941, 2022 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007321
8.
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial.
Haematologica
; 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38268448
9.
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.
Value Health
; 27(5): 607-613, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38311180
10.
Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.
Cancer
; 129(11): 1681-1690, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36840971
11.
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia.
Haematologica
; 108(6): 1555-1566, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36700403
12.
Evaluation of the Prescribing Skills Assessment implementation, performance and medical student experience in Australia and New Zealand.
Br J Clin Pharmacol
; 89(10): 3105-3115, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37276579
13.
How I manage myeloproliferative neoplasm-unclassifiable: Practical approaches for 2022 and beyond.
Br J Haematol
; 197(4): 407-416, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35191542
14.
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
Br J Haematol
; 198(2): 317-327, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35476316
15.
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype.
Br J Haematol
; 198(6): 1011-1015, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35802024
16.
Current and future status of JAK inhibitors.
Lancet
; 398(10302): 803-816, 2021 08 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34454676
17.
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Haematologica
; 107(7): 1599-1607, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551507
18.
Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.
Ann Hematol
; 101(1): 131-137, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34625831
19.
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
Future Oncol
; 18(22): 2393-2402, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35510486
20.
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Future Oncol
; 18(27): 2987-2997, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35950489